Uridine prevents tamoxifen-induced liver lipid droplet accumulation

BMC Pharmacology and Toxicology

Giuseppe Pizzorno²  Yasuyo Urasaki¹  Thuc T Le¹ 

[1] Roseman University of Health Sciences, 11 Sunset Way, Henderson NV 89014, USA;Desert Research Institute, 10530 Discovery Drive, Las Vegas, NV 89135, USA

关键词: Uridine phosphorylase;    Triacylglyceride;    Tamoxifen;    Pyrimidine;    Protein lysine acetylation;    Mitochondrial respiration;    Membrane phospholipid;    Lipidomics;    Drug-induced fatty liver;    Coherent anti-Stokes Raman scattering microscopy;   

Others  :  848382
DOI  :  10.1186/2050-6511-15-27

 received in 2014-01-24, accepted in 2014-04-30,  发布年份 2014

【 摘 要 】

Background

Tamoxifen, an agonist of estrogen receptor, is widely prescribed for the prevention and long-term treatment of breast cancer. A side effect of tamoxifen is fatty liver, which increases the risk for non-alcoholic fatty liver disease. Prevention of tamoxifen-induced fatty liver has the potential to improve the safety of long-term tamoxifen usage.

Methods

Uridine, a pyrimidine nucleoside with reported protective effects against drug-induced fatty liver, was co-administered with tamoxifen in C57BL/6J mice. Liver lipid levels were evaluated with lipid visualization using coherent anti-Stokes Raman scatting (CARS) microscopy, biochemical assay measurement of triacylglyceride (TAG), and liquid chromatography coupled with mass spectrometry (LC-MS) measurement of membrane phospholipid. Blood TAG and cholesterol levels were measured. Mitochondrial respiration of primary hepatocytes in the presence of tamoxifen and/or uridine was evaluated by measuring oxygen consumption rate with an extracellular flux analyzer. Liver protein lysine acetylation profiles were evaluated with 1D and 2D Western blots. In addition, the relationship between endogenous uridine levels, fatty liver, and tamoxifen administration was evaluated in transgenic mice UPase1^−/−and UPase1-TG.

Results

Uridine co-administration prevented tamoxifen-induced liver lipid droplet accumulation in mice. The most prominent effect of uridine co-administration with tamoxifen was the stimulation of liver membrane phospholipid biosynthesis. Uridine had no protective effect against tamoxifen-induced impairment to mitochondrial respiration of primary hepatocytes or liver TAG and cholesterol export. Uridine had no effect on tamoxifen-induced changes to liver protein acetylation profile. Transgenic mice UPase1^−/−with increased pyrimidine salvage activity were protected against tamoxifen-induced liver lipid droplet accumulation. In contrast, UPase1-TG mice with increased pyrimidine catabolism activity had intrinsic liver lipid droplet accumulation, which was aggravated following tamoxifen administration.

Conclusion

Uridine co-administration was effective at preventing tamoxifen-induced liver lipid droplet accumulation. The ability of uridine to prevent tamoxifen-induced fatty liver appeared to depend on the pyrimidine salvage pathway, which promotes biosynthesis of membrane phospholipid.

【 授权许可】

   
2014 Le et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998, 90(18):1371-1388.
• [2]Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M: Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011, 29(13):1657-1663.
• [3]Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska , Kwan WH, Matthew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, et al.: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381(9869):805-816.
• [4]Nishino M, Hayakawa K, Nakamura Y, Morimoto T, Mukaihara S: Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol 2003, 180(1):129-134.
• [5]Ogawa Y, Murata Y, Nishioka A, Inomata T, Yoshida S: Tamoxifen-induced fatty liver in patients with breast cancer. Lancet 1998, 351(9104):725.
• [6]Nguyen MC, Stewart RB, Banerji MA, Gordon DH, Kral JG: Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 2001, 25(2):296-298.
• [7]Cohen JC, Horton JD, Hobbs HH: Human fatty liver disease: old questions and new insights. Science 2011, 332(6037):1519-1523.
• [8]Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D, Desiderio F, Stroffolini T, Sacchini V, Decensi A, Veronesi U: Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005, 330(7497):932.
• [9]Cardoso CM, Custodio JB, Almeida LM, Moreno AJ: Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 2001, 176(3):145-152.
• [10]Lelliott CJ, Lopez M, Curtis RK, Parker N, Laudes M, Yeo G, Jimenez-Linan M, Grosse J, Saha AK, Wiggins D, Hauton D, Brand MD, O’Rahilly S, Griffin JL, Gibbons GF, Vidal-Puig A: Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J 2005, 19(9):1108-1119.
• [11]Larosche I, Letteron P, Fromenty B, Vadrot N, Abbey-Toby A, Feldmann G, Pessayre D, Mansouri A: Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 2007, 321(2):526-535.
• [12]Gudbrandsen OA, Rost TH, Berge RK: Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J Lipid Res 2006, 47(10):2223-2232.
• [13]Lebrecht D, Vargas-Infante YA, Setzer B, Kirschner J, Walker UA: Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007, 45(1):72-79.
• [14]Le TT, Urasaki Y, Pizzorno G: Uridine prevents fenofibrate-induced fatty liver. PLoS One 2014, 9(1):e87179.
• [15]Connolly GP, Duley JA: Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci 1999, 20(5):218-225.
• [16]Pizzorno G, Cao D, Leffert JJ, Russell RL, Zhang D, Handschumacher RE: Homeostatic control of uridine and the role of uridine phosphorylase: a biological and clinical update. Biochim Biophys Acta 2002, 1587(2–3):133-144.
• [17]Cao D, Leffert JJ, McCabe J, Kim B, Pizzorno G: Abnormalities in uridine homeostatic regulation and pyrimidine nucleotide metabolism as a consequence of the deletion of the uridine phosphorylase gene. J Biol Chem 2005, 280(22):21169-21175.
• [18]Le TT, Ziemba A, Urasaki Y, Hayes E, Brotman S, Pizzorno G: Disruption of uridine homeostasis links liver pyrimidine metabolism to lipid accumulation. J Lipid Res 2013, 54(4):1044-1057.
• [19]Gasser T, Moyer JD, Handschumacher RE: Novel single-pass exchange of circulating uridine in rat liver. Science 1981, 213(4509):777-778.
• [20]Urasaki Y, Johlfs MG, Fiscus RR, Le TT: Imaging immune and metabolic cells of visceral adipose tissues with multimodal nonlinear optical microscopy. PLoS One 2012, 7(6):e38418.
• [21]Le TT, Ziemba A, Urasaki Y, Brotman S, Pizzorno G: Label-free evaluation of hepatic microvesicular steatosis with multimodal coherent anti-stokes Raman scattering microscopy. PLoS One 2012, 7(11):e51092.
• [22]Evans CL, Xie XS: Coherent anti-Stokes Raman scattering microscopy: chemically selective imaging for biology and medicine. Annu Rev Anal Chem 2008, 1(1):883-909.
• [23]Le TT, Yue S, Cheng JX: Shedding new light on lipid biology with coherent anti-Stokes Raman scattering microscopy. J Lipid Res 2010, 51(11):3091-3102.
• [24]Zhang J, Nuebel E, Wisidagama DR, Setoguchi K, Hong JS, Van Horn CM, Imam SS, Vergnes L, Malone CS, Koehler CM, Teitell MA: Measuring energy metabolism in cultured cells, including human pluripotent stem cells and differentiated cells. Nat Protoc 2012, 7(6):1068-1085.
• [25]Robinson SP, Langan-Fahey SM, Johnson DA, Jordan VC: Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab Dispos 1991, 19(1):36-43.
• [26]Pezacki JP, Blake JA, Danielson DC, Kennedy DC, Lyn RK, Singaravelu R: Chemical contrast for imaging living systems: molecular vibrations drive CARS microscopy. Nat Chem Biol 2011, 7(3):137-145.
• [27]Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ, Nonalcoholic Steatohepatitis Clinical Research Network: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41(6):1313-1321.
• [28]Garcia Urena MA, Colina Ruiz-Delgado F, Moreno Gonzalez E, Jimenez Romero C, Garcia Garcia I, Loinzaz Segurola C, Gonzalez P, Gomez Sanz R: Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg 1998, 22(8):837-844.
• [29]Markin RS, Wisecarver JL, Radio SJ, Stratta RJ, Langnas AN, Hirst K, Shaw BW Jr: Frozen section evaluation of donor livers before transplantation. Transplantation 1993, 56(6):1403-1409.
• [30]El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, Puhan MA, Slankamenac K, Graf R, Clavien PA: Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009, 250(5):691-697.
• [31]Kendrick AA, Choudhury M, Rahman SM, McCurdy CE, Friederich M, Van Hove JL, Watson PA, Birdsey N, Bao J, Gius D, Sack MN, Jing E, Kahn CR, Friedman JE, Jonscher KR: Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 2011, 433(3):505-514.
• [32]Hirschey MD, Shimazu T, Jing E, Grueter CA, Collins AM, Aouizerat B, Stancakova A, Goetzman E, Lam MM, Schwer B, Stevens RD, Muehlbauer MJ, Kakar S, Bass NM, Kuusisto J, Laakso M, Alt FW, Newgard CB, Farese RV Jr, Kahn CR, Verdin E: SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 2011, 44(2):177-190.
• [33]Kent C: Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995, 64:315-343.
• [34]Cao D, Ziemba A, McCabe J, Yan R, Wan L, Kim B, Gach M, Flynn S, Pizzorno G: Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity. Mol Cancer Ther 2011, 10(12):2330-2339.
• [35]Cai J, Lee CW: Tamoxifen inhibits nitrobenzylthioinosine-sensitive equilibrative uridine transport in human MCF-7 breast cancer cells. Biochem J 1996, 320(Pt 3):991-995.
• [36]Traut TW, Jones ME: Uracil metabolism–UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Prog Nucleic Acid Res Mol Biol 1996, 53:1-78.
• [37]Pizzorno G, Yee L, Burtness BA, Marsh JC, Darnowski JW, Chu MY, Chu SH, Chu E, Leffert JJ, Handschumacher RE, Calabresi P: Phase I clinical and pharmacological studies of benzylacyclouridine, a uridine phosphorylase inhibitor. Clin Cancer Res 1998, 4(5):1165-1175.